Publications by authors named "Denis N Kisakov"
Article Synopsis
- The H5N8 avian influenza virus poses a risk to bird populations and potential human health concerns, necessitating the development of a safe and effective vaccine.
- Researchers created an experimental pVAX-H5 DNA vaccine that encodes a modified version of the virus's hemagglutinin and tested it on mice, resulting in a strong antibody and T-cell response.
- Both liquid and lyophilized versions of the pVAX-H5 vaccine provided complete protection for mice against lethal influenza A virus challenges, showing promise as a candidate for combating H5N8.
In this study, we characterized recombinant hemagglutinin (HA) of influenza A (H5N8) virus produced in Chinese hamster ovary cells (CHO-K1s). Immunochemical analysis showed that the recombinant hemagglutinin was recognized by the serum of ferrets infected with influenza A (H5N8) virus, indicating that its antigenic properties were retained. Two groups of Balb/c mice were immunized with intramuscular injection of recombinant hemagglutinin or propiolactone inactivated A/Astrakhan/3212/2020 (H5N8) influenza virus.
View Article and Find Full Text PDFIntroduction: Nucleic acids represent a promising platform for creating vaccines. One disadvantage of this approach is its relatively low immunogenicity. Electroporation (EP) is an effective way to increase the DNA vaccines immunogenicity.
View Article and Find Full Text PDFOptimization of In Vivo Electroporation Conditions and Delivery of DNA Vaccine Encoding SARS-CoV-2 RBD Using the Determined Protocol.
Pharmaceutics
October 2022
Vaccination against SARS-CoV-2 and other viral infections requires safe, effective, and inexpensive vaccines that can be rapidly developed. DNA vaccines are candidates that meet these criteria, but one of their drawbacks is their relatively weak immunogenicity. Electroporation (EP) is an effective way to enhance the immunogenicity of DNA vaccines, but because of the different configurations of the devices that are used for EP, it is necessary to carefully select the conditions of the procedure, including characteristics such as voltage, current strength, number of pulses, etc.
View Article and Find Full Text PDFArticle Synopsis
- The conventional live smallpox vaccine, based on the vaccinia virus (VACV), has limitations due to high reactogenicity, prompting the need for safer VACV variants with better immune responses.
- This study explores low-dose VACV variants with genetic modifications that boost immune responses, specifically looking at humoral and T cell-mediated immunity in mice.
- The research found that the LIVP-A34R*-dA35R variant produced the strongest T cell-mediated immunity and higher antibody levels compared to the parental LIVP strain, suggesting that combining gene modification and deletion enhances the vaccine's effectiveness.
Mass vaccination has played a critical role in the global eradication of smallpox. Various vaccinia virus (VACV) strains, whose origin has not been clearly documented in most cases, have been used as live vaccines in different countries. These VACV strains differed in pathogenicity towards various laboratory animals and in reactogenicity exhibited upon vaccination of humans.
View Article and Find Full Text PDF